Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

February 21, 2017

Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia

January 20, 2017

Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function

December 20, 2016

Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer

December 5, 2016

Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting

November 10, 2016

Minerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016

November 3, 2016

Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates

October 27, 2016

Minerva Neurosciences to Report Third Quarter 2016 Financial Results and Business Updates on November 3, 2016

October 26, 2016

Minerva Neurosciences Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia

October 13, 2016

Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting

September 26, 2016

Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs

«...14 151617 18...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top